长春百克生物科技股份公司 第六届监事会第二次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2025 年 4 月 17 日，长春百克生物科技股份公司（以下简称"公司"）第六 届监事会第二次会议以现场会议及通讯方式召开，本次会议由监事会主席冯大强 先生主持，会议应到监事 3 名，实到监事 3 名，符合《中华人民共和国公司法》 和《长春百克生物科技股份公司章程》（以下简称"《公司章程》"）规定的法 定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： 证券代码：688276 证券简称：百克生物 公告编号：2025-012 （一）审议通过《<2024 年年度报告>全文及摘要》 监事会认为：公司 2024 年年度报告的编制和审议程序符合相关法律法规及 《公司章程》等内部规章制度的规定；公司 2024 年年度报告的内容与格式符合 中国证监会和上海证券交易所的各项规定，所包含的信息能够真实、准确、完整 地反映公司 2024 年度的财务状况和经营成果 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-011 长春百克生物科技股份公司 第六届董事会第五次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2025 年 4 月 17 日，长春百克生物科技股份公司（以下简称"公司"）第六 届董事会第五次会议以现场会议及通讯方式召开，本次会议由董事长李秀峰先生 主持，会议应到董事 11 名，实到董事 11 名，符合《中华人民共和国公司法》和 《长春百克生物科技股份公司章程》规定的法定人数，本次董事会会议决议合法 有效。 （二）审议通过《2024 年度利润分配预案》 表决情况：11 票赞成，0 票反对，0 票弃权。 二、董事会会议审议情况 经与会董事审议表决，一致通过如下议案： （一）审议通过《<2024 年年度报告>全文及摘要》 表决情况：11 票赞成，0 票反对，0 票弃权。 本议案已通过公司审计委员会事前审议。 本议案尚需提交股东会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《长 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-013 长春百克生物科技股份公司 重要内容提示： 每股分配比例：每 10 股派发现金红利人民币 1.69 元（含税），不送红股， 不进行资本公积转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 如在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 本次利润分配未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》（以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规 定的可能被实施其他风险警示的情形。 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 项目 | 2024年度 | 2023年度 | 2022年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 69,908,134.06 | 62,048,639.70 | 61 ...

Financial Performance - The company's revenue for Q1 2025 was ¥162,290,516.78, a decrease of 39.96% compared to ¥270,288,441.14 in the same period last year[4] - Net profit attributable to shareholders was ¥1,064,275.78, down 98.24% from ¥60,565,065.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was -¥3,411,965.39, representing a decline of 105.71% compared to ¥59,803,967.25 in the previous year[4] - The company reported a total comprehensive income of -¥3,554,830.30 for Q1 2025, compared to ¥52,979,886.88 in Q1 2024[23] - Basic and diluted earnings per share for Q1 2025 were both ¥0.00, compared to ¥0.15 in Q1 2024[23] - The net loss for Q1 2025 was CNY 2,487,647.36, a significant decline compared to a profit of CNY 65,632,514.01 in Q1 2024[31] - The total comprehensive income for the first quarter of 2025 was CNY -2,588,300.46, contrasting with CNY 54,510,490.93 in the first quarter of 2024[32] Cash Flow - The net cash flow from operating activities was -¥68,805,373.58, worsening from -¥7,933,515.62 in the same period last year[4] - Operating cash flow for Q1 2025 was negative at -¥68,805,373.58, compared to -¥7,933,515.62 in Q1 2024[26] - Cash flow from operating activities for Q1 2025 was CNY -68,809,529.80, compared to CNY -7,939,865.44 in Q1 2024, indicating a worsening cash flow situation[35] - The net cash flow from investing activities was -CNY 123,751,836.25, compared to -CNY 86,292,352.83 in the previous period, indicating a significant increase in cash outflow[27] - Cash inflow from financing activities in Q1 2025 was CNY 71,834,374.47, an increase from CNY 44,415,955.34 in Q1 2024[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,352,186,880.18, an increase of 2.83% from ¥5,204,868,837.55 at the end of the previous year[5] - The total liabilities increased to ¥1,137,016,519.35 in the latest report, up from ¥987,120,567.56[20] - The total assets as of March 31, 2025, amounted to CNY 5,652,254,361.52, an increase from CNY 5,503,880,417.19 as of December 31, 2024[31] - The total liabilities increased to CNY 1,134,869,744.86 from CNY 984,884,421.21, reflecting a rise in financial obligations[30] Research and Development - R&D investment totaled ¥36,858,462.61, a decrease of 21.48% from ¥46,940,335.50, while the proportion of R&D investment to revenue increased by 5.34 percentage points to 22.71%[5] - R&D expenses for Q1 2025 were ¥36,858,462.61, down 21.5% from ¥46,940,335.50 in Q1 2024[22] - The company is actively pursuing new product development and clinical trials for innovative vaccines, including a new mRNA tumor vaccine[14] - The company has submitted clinical trial applications for its restructured shingles vaccine and adjuvanted flu vaccine, which have been accepted[14] - The company is expanding its product pipeline, including adult vaccines and mRNA technology, to enhance its core competitiveness[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,054[8] - The largest shareholder, Changchun High-tech Industry (Group) Co., Ltd., holds 41.46% of the shares, totaling 171,488,182 shares[9] - Total equity attributable to shareholders was ¥4,215,170,360.83, slightly down from ¥4,217,748,269.99[20] - The company's total equity decreased slightly to CNY 4,517,384,616.66 from CNY 4,518,995,995.98, reflecting a minor reduction in shareholder value[31] Sales and Marketing - The company reported a decline in sales and net profit due to external factors, including reduced demand for the shingles vaccine, with a focus on optimizing marketing strategies[14] - The company plans to expand its sales channels and increase promotional efforts, which contributed to the rise in sales expenses[6] - Sales expenses in Q1 2025 were ¥73,607,698.35, a decrease of 26.3% from ¥99,954,306.04 in Q1 2024[22] - Cash inflow from sales of goods and services in Q1 2025 was CNY 176,473,731.79, down from CNY 253,656,020.12 in Q1 2024, reflecting a decline of approximately 30.4%[34] Future Outlook - The company plans to implement new accounting standards starting from 2025, which may affect future financial reporting[36]

Financial Performance - The company's operating revenue for 2024 was CNY 1,229,084,097.15, a decrease of 32.64% compared to CNY 1,824,688,777.32 in 2023[26]. - Net profit attributable to shareholders for 2024 was CNY 232,093,825.73, down 53.67% from CNY 501,009,182.39 in 2023[26]. - The net profit after deducting non-recurring gains and losses was CNY 229,810,386.80, a decrease of 53.42% compared to CNY 493,358,270.16 in the previous year[26]. - The gross profit margin for the main business is 85.42%, down by 4.82 percentage points from the previous year[105]. - The company reported a 42.50% decrease in non-operating income, mainly due to reduced insurance claims compared to the previous year[105]. - The company achieved total revenue of 1,229.08 million yuan, a decrease of 32.64% compared to the previous year's revenue of 1,824.69 million yuan[102]. - Net profit attributable to the parent company was 232.09 million yuan, down 53.67% from 501.01 million yuan in the same period last year[102]. - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion yuan in the latest quarter[195]. - The company reported a net profit margin of 18%, reflecting improved operational efficiency[196]. Research and Development - The company is focusing on innovation-driven development, with progress in multiple research products including liquid nasal spray flu vaccine and rabies monoclonal antibody[39]. - The company has 16 major projects under research, with 7 projects in clinical trial approval and registration stages, and R&D investment of CNY 156.14 million, accounting for 12.70% of revenue[40]. - The company is developing multiple vaccines, including a liquid nasal flu vaccine and a recombinant shingles vaccine, with significant progress reported in clinical trials[140]. - The company has established five core technology platforms for vaccine development, including virus large-scale culture technology and mRNA vaccine technology[52]. - The company is committed to continuous R&D investment to maintain its competitive edge and support sustainable growth in the biopharmaceutical industry[61]. - The total R&D expenditure for the year was approximately ¥156.14 million, a decrease of 21.43% compared to the previous year, with R&D expenses accounting for 12.70% of operating revenue, an increase of 1.81 percentage points[70]. - The company is focusing on expanding its product pipeline and enhancing its research capabilities to meet the growing demand for innovative vaccines[57]. - The company has submitted IND applications for multiple vaccines, including the recombinant herpes zoster vaccine and the adjuvant flu vaccine, both of which have received acceptance notifications[75]. - The company is preparing to launch clinical trials for its HSV-2 vaccine, which has received approval for trial applications[142]. Market Strategy and Expansion - The company is actively expanding its international market, with the first exports of the shingles vaccine to Colombia and the chickenpox vaccine to Afghanistan, reaching over 10 countries[43]. - The company is focusing on enhancing its product pipeline in adult vaccines, multi-valent vaccines, and therapeutic vaccines, as well as mRNA technology[87]. - The company is exploring acquisition opportunities to enhance its product portfolio, targeting a potential acquisition valued at 500 million yuan[195]. - The company plans to optimize its marketing system and increase public awareness of related diseases to stimulate user demand[87]. - The company is actively adjusting its marketing strategies in response to market dynamics to achieve high-quality development[39]. - The company aims to enhance its brand recognition and influence through professional marketing strategies and collaborations with academic promotion personnel[53]. - The company plans to increase its marketing budget by 25% to support new product launches and market expansion[199]. Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for providing guarantees[10]. - The company has not faced any issues with the majority of directors being unable to ensure the authenticity, accuracy, and completeness of the annual report[12]. - The company updated 20 governance documents to align with regulatory requirements, enhancing governance transparency and compliance[182]. - The company successfully held two shareholder meetings during the reporting period, with all proposed resolutions approved[184]. Financial Health and Risks - The total assets at the end of 2024 were CNY 5,204,868,837.55, a 3.14% increase from CNY 5,046,237,662.74 in 2023[26]. - The net cash flow from operating activities increased by 59.28% to CNY 406,502,236.83 from CNY 255,206,956.72 in 2023[26]. - The company reported a high accounts receivable net amount of 1,405.67 million yuan, accounting for 71.55% of current assets, indicating potential liquidity risks[97]. - The company faces risks related to clinical trial progress and potential delays in product commercialization[91][92]. - The company received a tax benefit of 13.48 million yuan as a high-tech enterprise, which may be affected by future policy changes[98]. Talent Development and Management - The company is focusing on talent development and internal control management to enhance operational efficiency and sustainability[47][48]. - The company has a research team of 133 people, accounting for 10.44% of the total workforce, with an average salary of RMB 17.01 million for R&D personnel[79]. - The company plans to attract and cultivate high-quality talent in R&D, production, and sales to support long-term development and innovation[172]. - The company will optimize its compensation and performance management system to maximize employee effectiveness and support sustainable development[178].

值得注意的是，近日，百克生物参股公司传信生物医药(苏州)有限公司自主研发的"新型mRNA肿瘤疫苗 TMT101"开展的一项"研究者发起的临床试验"在中国医学科学院北京协和医院顺利完成首例患者给药及 剂量限制性毒性(DLT)观察，未出现DLT事件，TMT101是传信生物自主研发的新型mRNA肿瘤疫苗，进 入体内后可由脂质纳米颗粒(LNP)递送至细胞，编码产生的肿瘤相关抗原(TAA)能够被抗原呈递细胞 (APC)有效提呈并刺激产生特异性的T细胞反应，进而达到杀伤肿瘤细胞和治疗癌症的目的，有望在"泛 癌种"治疗中发挥作用。 2024年，面对同类产品的价格调整以及新竞品获批上市等带来的挑战，百克生物紧密关注市场动态，积 极调整市场营销策略，公司与阿里健康、百度、知乎、小红书等流量平台建立合作关系，积极开发公众 号资源，借助流量平台，打通多渠道流量入口。此外，与疫苗专业平台合作，如小豆苗、约苗，结合文 章科普教育触达用户，通过精准投放实现用户转化，进而实现线上营销。线下渠道方面，通过与医院智 慧屏的合作，利用线下渠道进行精准广告投放，从而优化客户获取流程并提升转化率。 百克生物(688276)4月20日晚发布2024年 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-010 长春百克生物科技股份公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 21 日（星期一）上午 09:00-10:00 （三）会议召开方式：上证路演中心网络互动 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 14 日（星期一）至 4 月 18 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司（以下简称"公司"）将于 2025 年 4 月 21 日发 布公司 2024 年年度报告及 2025 年第一季度报告，为便于广 ...

北京植德律师事务所 关于长春百克生物科技股份公司 2025 年第一次临时股东会的 法律意见书 植德京（会）字[2025]0023号 二〇二五年四月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Offices Tower, No.1 Dongzhimen South Street,Dongcheng District, Beijing 100007 P.R.C. 电话（Tel）: 010-56500900 传真（Fax）: 010-56500999 www.meritsandtree.com 北京植德律师事务所 关于长春百克生物科技股份公司 2025 年第一次临时股东会的 法律意见书 植德京（会）字[2025]0023 号 致：长春百克生物科技股份公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席 并见证贵公司 2025 年第一次临时股东会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-009 长春百克生物科技股份公司 2025 年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 4 月 7 日 （二） 股东会召开的地点：长春百克生物科技股份公司 5 楼会议室（吉林省长 春市卓越大街 138 号） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 87 | | --- | --- | | 普通股股东人数 | 87 | | 2、出席会议的股东所持有的表决权数量 | 289,968,348 | | 普通股股东所持有表决权数量 | 289,968,348 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 70.0986 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 70.09 ...

长春百克生物科技股份公司 2025 年第一次临时股东会会议资料 二零二五年四月 | 股东会会议须知---------------------------------------------------------------------------------2 | | --- | | 股东会会议议程---------------------------------------------------------------------------------4 | | 股东会会议议案---------------------------------------------------------------------------------6 | | 议案一：关于补选第六届董事会非独立董事的议案-----------------------------6 | | 附件：候选人简历------------------------------------------------------------------------7 | 百克生物 2025 年第一次临时股东会会议资料 2025 年第一次临时股东会会 ...